BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/18/2022 12:26:44 PM | Browse: 838 | Download: 2111
Publication Name World Journal of Psychiatry
Manuscript ID 71664
Country Kuwait
ISSN 2220-3206 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Psychiatry
Manuscript Type Letter to the Editor
Article Title Therapeutic use of melatonin in schizophrenia-more than meets the eye!
Manuscript Source Invited Manuscript
All Author List Ahmed Naguy
ORCID
Author(s) ORCID Number
Ahmed Naguy http://orcid.org/0000-0002-6465-456X
Funding Agency and Grant Number
Corresponding Author Ahmed Naguy, MBChB, MSc, Staff Physician, Al-Manara CAP Centre, Kuwait Centre for Mental health (KCMH), Jamal Abdul-Nassir Street, Shuwaikh 22094, Kuwait. ahmednagy@hotmail.co.uk
Key Words Melatonin; Schizophrenia; Chronobiotic; Neuroprotectant; Antipsychotic; Tardive dyskinesia; Metabolic syndrome
Core Tip Adjuventia Melatonin use in schizophrenia is strongly recommended. This is supported by a modicum of evidence base. Use is multi-folded transcending chronobiotic actions, rectifying sleep disturbance in schizophrenia, to bona fide augmentative antipsychotic actions, mitigating the risk of relentless tardive dyskinesias, curbing the drastic cardio-metabolic syndrome and ultimately neuroprotective actions in the face of neuroprogressive course of schizophrenia over time.
Publish Date 2022-03-18 12:26
Citation Naguy A. Therapeutic use of melatonin in schizophrenia-more than meets the eye!. World J Psychiatry 2022; 12(3): 533-535
URL https://www.wjgnet.com/2220-3206/full/v12/i3/533.htm
DOI https://dx.doi.org/10.5498/wjp.v12.i3.533
Full Article (PDF) WJP-12-533.pdf
Full Article (Word) WJP-12-533.docx